Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Purchased by Lazard Asset Management LLC

Lazard Asset Management LLC boosted its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 525.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 537,669 shares of the company's stock after acquiring an additional 451,737 shares during the quarter. Lazard Asset Management LLC owned 1.11% of Axsome Therapeutics worth $45,492,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in AXSM. Assetmark Inc. purchased a new stake in Axsome Therapeutics in the fourth quarter worth about $52,000. R Squared Ltd purchased a new stake in Axsome Therapeutics during the 4th quarter valued at $64,000. Aquatic Capital Management LLC purchased a new stake in shares of Axsome Therapeutics in the 4th quarter worth $76,000. KBC Group NV boosted its holdings in Axsome Therapeutics by 40.5% in the 4th quarter. KBC Group NV now owns 1,336 shares of the company's stock worth $113,000 after buying an additional 385 shares during the period. Finally, Xponance Inc. boosted its holdings in Axsome Therapeutics by 11.6% in the 4th quarter. Xponance Inc. now owns 2,659 shares of the company's stock worth $225,000 after buying an additional 277 shares during the period. Institutional investors own 81.49% of the company's stock.

Analysts Set New Price Targets

AXSM has been the subject of several research reports. Cantor Fitzgerald raised shares of Axsome Therapeutics to a "strong-buy" rating in a report on Wednesday. Morgan Stanley raised their target price on shares of Axsome Therapeutics from $125.00 to $190.00 and gave the stock an "overweight" rating in a research report on Thursday, February 27th. Truist Financial increased their price objective on shares of Axsome Therapeutics from $190.00 to $200.00 and gave the company a "buy" rating in a research note on Wednesday, February 19th. Royal Bank of Canada increased their price objective on shares of Axsome Therapeutics from $190.00 to $193.00 and gave the company an "outperform" rating in a research note on Tuesday, April 29th. Finally, Robert W. Baird raised their target price on shares of Axsome Therapeutics from $160.00 to $162.00 and gave the company an "outperform" rating in a research note on Tuesday, May 6th. One research analyst has rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $172.14.

Axsome Therapeutics Stock Performance

AXSM traded up $0.31 on Friday, reaching $107.53. The stock had a trading volume of 627,730 shares, compared to its average volume of 688,043. Axsome Therapeutics, Inc. has a 12-month low of $64.11 and a 12-month high of $139.13. The company has a current ratio of 2.11, a quick ratio of 2.04 and a debt-to-equity ratio of 3.22. The business's 50-day moving average price is $110.49 and its two-hundred day moving average price is $105.08. The company has a market cap of $5.29 billion, a P/E ratio of -17.95 and a beta of 0.46.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last released its earnings results on Tuesday, February 18th. The company reported ($0.96) EPS for the quarter, topping analysts' consensus estimates of ($0.97) by $0.01. The business had revenue of $118.77 million during the quarter, compared to analysts' expectations of $117.83 million. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. Sell-side analysts forecast that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.